It’s good to see that Johnson & Johnson (and the National Academy of Medicine) has finally gotten on board with the idea that humans could life very long lives in good health. This is an idea for which we (and…
Gene therapies will be unaffordable to most unless there is a technical/economic breakthrough. Patient costs for gene therapies (after insurance) of $520,000 is not affordable for most people. Patient costs of $65,500 a year for five years is still not…
This may be of value for certain new therapies, and patients with no other options. What is Right To Try? The FDA FAQ on Right To Try How Right To Try differs from FDA Expanded Access
JAMA study on the cost of new drug development, published in 2018. https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2702287 CenterPoint data on the cost of new drug development, broken down by therapeutic area. Published in 2016. https://www.centerpointclinicalservices.com/blog-posts/driving-drive-drug-innovation-and-market-access-part-1-clinical-trial-cost-breakdown/ US Department of Health & Human Services study on…
Below are three articles describing the details of the biggest obstacle to gene therapy adoption: the cost. From the UK’s Independent: Gene therapy is now available, but could cost millions over a lifetime, says scientists From Scientific American: Gene Therapy…
More excellent and thoughtful analysis by Dr. Mike Fossel on the science of aging and telomeres. Our favorite excerpts: “To truly understand how aging works, you need to erase your assumptions, step back, and look at the complexity without blinders…
A collection of articles providing additional analysis and commentary about the cost of new drug development. Policy & Medicine, Johns Hopkins School of Public Health, and Forbes, all agree that the cost of new drug development is unnecessarily high.
We focus more on the science of life extension than the business of life extension. However the business of life extension helps to enable the science, and therefore we must also have appropriate focus on the financial and industry realities…
Below is an interview with Doug Casey regarding some of the philosophical aspects of life extension science. Our standard disclaimer applies: we do not agree with everything that Mr. Casey has to say, but we agree with much of it,…
Below are a series of insightful commentaries published at fightaging.org regarding the excessively expensive and heavy-handed nature of regulation of new medical therapies in advanced countries. We happen to agree with much of this assessment, which is why we have…
Enter your details below to save your shopping cart for later. And, who knows, maybe we will even send you a sweet discount code :)